AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteBleomycin sulfate is a mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.
More Information Supplier PageBleomycin sulfate is a mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.
More Information Supplier PageBleomycin sulfate is a mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.
More Information Supplier PageBleomycin sulfate is a mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.
More Information Supplier PageBleomycin sulfate is a mixture of the sulfate salts of basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.
More Information Supplier PageBlonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.
More Information Supplier PageBlonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.
More Information Supplier PageBlonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.
More Information Supplier PageBlonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.
More Information Supplier PageBLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM),
More Information Supplier PageBLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM),
More Information Supplier PageBLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM),
More Information Supplier PageBLZ945 is a potent and selective CSF-1R kinase inhibitor. It attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas.
More Information Supplier PageBLZ945 is a potent and selective CSF-1R kinase inhibitor. It attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas.
More Information Supplier PageBLZ945 is a potent and selective CSF-1R kinase inhibitor. It attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas.
More Information Supplier PageBM-1074 is a potent and efficacious Bcl-2/Bcl-xL inhibitor with Ki of
More Information Supplier PageBM-1074 is a potent and efficacious Bcl-2/Bcl-xL inhibitor with Ki of
More Information Supplier PageBM-1074 is a potent and efficacious Bcl-2/Bcl-xL inhibitor with Ki of
More Information Supplier PageBM-1074 is a potent and efficacious Bcl-2/Bcl-xL inhibitor with Ki of
More Information Supplier PageBMH-21 is a potent small molecule DNA intercalator. BMH-21 binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.
More Information Supplier PageBMH-21 is a potent small molecule DNA intercalator. BMH-21 binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.
More Information Supplier PageBMH-21 is a potent small molecule DNA intercalator. BMH-21 binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.
More Information Supplier PageBML-190 is a selective inverse agonist of the human cannabinoid CB2 receptor.
More Information Supplier PageBML-190 is a selective inverse agonist of the human cannabinoid CB2 receptor.
More Information Supplier PageBML-190 is a selective inverse agonist of the human cannabinoid CB2 receptor.
More Information Supplier PageBML-190 is a selective inverse agonist of the human cannabinoid CB2 receptor.
More Information Supplier PageBML-275 is a cell-permeable pyrazolopyrimidine compound shown to be an AMP-activated protein kinase (AMPK) and fatty acid synthase inhibitor.
More Information Supplier PageBML-275 is a cell-permeable pyrazolopyrimidine compound shown to be an AMP-activated protein kinase (AMPK) and fatty acid synthase inhibitor.
More Information Supplier PageBML-275 is a cell-permeable pyrazolopyrimidine compound shown to be an AMP-activated protein kinase (AMPK) and fatty acid synthase inhibitor.
More Information Supplier PageBML-277 (Chk2 Inhibitor II) is a Chk2 (checkpoint kinase 2) inhibitor.
More Information Supplier PageBML-277 (Chk2 Inhibitor II) is a Chk2 (checkpoint kinase 2) inhibitor.
More Information Supplier PageBML-277 (Chk2 Inhibitor II) is a Chk2 (checkpoint kinase 2) inhibitor.
More Information Supplier PageBML-277 (Chk2 Inhibitor II) is a Chk2 (checkpoint kinase 2) inhibitor.
More Information Supplier PageBMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673. BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM(PARP1).
More Information Supplier PageBMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673. BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM(PARP1).
More Information Supplier PageBMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673. BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM(PARP1).
More Information Supplier PageBMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
More Information Supplier PageBMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
More Information Supplier PageBMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
More Information Supplier PageBMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
More Information Supplier PageBMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
More Information Supplier PageBMPS is a short, sulfhydryl and amino reactive heterobifunctional crosslinking reagent.
More Information Supplier PageBMPS is a short, sulfhydryl and amino reactive heterobifunctional crosslinking reagent.
More Information Supplier PageBMPS is a short, sulfhydryl and amino reactive heterobifunctional crosslinking reagent.
More Information Supplier PageBMS 299897 is an orally active, potent ??-secretase inhibitor (IC50 = 12 nM). Inhibits A??40 and A??42 formation in vitro (IC50 values are 7.4 and 7.9 nM respectively) and reduces A?? in the brain, plasma and cerebrospinal fluid in vivo.
More Information Supplier PageBMS 299897 is an orally active, potent ??-secretase inhibitor (IC50 = 12 nM). Inhibits A??40 and A??42 formation in vitro (IC50 values are 7.4 and 7.9 nM respectively) and reduces A?? in the brain, plasma and cerebrospinal fluid in vivo.
More Information Supplier PageBMS 299897 is an orally active, potent ??-secretase inhibitor (IC50 = 12 nM). Inhibits A??40 and A??42 formation in vitro (IC50 values are 7.4 and 7.9 nM respectively) and reduces A?? in the brain, plasma and cerebrospinal fluid in vivo.
More Information Supplier PageBMS 299897 is an orally active, potent ??-secretase inhibitor (IC50 = 12 nM). Inhibits A??40 and A??42 formation in vitro (IC50 values are 7.4 and 7.9 nM respectively) and reduces A?? in the brain, plasma and cerebrospinal fluid in vivo.
More Information Supplier PageBMS 345541 is a cell-permeable and highly selective IKB kinase (IKK) inhibitor that binds at allosteric site of the enzyme and blocks NF-kB-dependent transcription in mice.
More Information Supplier PageBMS 345541 is a cell-permeable and highly selective IKB kinase (IKK) inhibitor that binds at allosteric site of the enzyme and blocks NF-kB-dependent transcription in mice.
More Information Supplier Page
